MDPV: Difference between revisions

Line 15:

==Pharmacology==

MDPV acts as a [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[neurotransmitter]]s in the [[Synapse|synapse]], or junction between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] transmitters also experience a similar effect, although to a much lesser degree. This sudden increase in neurotransmitter levels in the brain is responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] in method of action ~~than amphetamine, which works primarily as an agonist to release dopamine and noradrenalin~~.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref>

MDPV acts as a [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[neurotransmitter]]s in the [[Synapse|synapse]], or junction between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] transmitters also experience a similar effect, although to a much lesser degree. This sudden increase in neurotransmitter levels in the brain is responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] than [[amphetamine]] in method of action.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> Amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.

==Subjective effects==

@@ Line 15: / Line 15: @@
 ==Pharmacology==
-MDPV acts as a [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[neurotransmitter]]s in the [[Synapse|synapse]], or junction between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] transmitters also experience a similar effect, although to a much lesser degree. This sudden increase in neurotransmitter levels in the brain is responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] in method of action than amphetamine, which works primarily as an agonist to release dopamine and noradrenalin.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref>
+MDPV acts as a [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[neurotransmitter]]s in the [[Synapse|synapse]], or junction between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] transmitters also experience a similar effect, although to a much lesser degree. This sudden increase in neurotransmitter levels in the brain is responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] than [[amphetamine]] in method of action.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> Amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.
 ==Subjective effects==